Navigation Links
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
Date:5/14/2009

Top-line data indicate statistically significant improvement in ACR20 responses over placebo

PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that the MDX-1100 Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) receiving methotrexate successfully met its primary endpoint. The top-line results from the recently completed 70-patient multi-center, randomized, double-blind, placebo-controlled Phase 2 trial indicated that when compared to placebo, three times the number of patients treated with 10 mg/kg of MDX-1100 every two weeks achieved at least a 20% improvement in RA signs and symptoms at 12 weeks, the primary endpoint of the study, as measured by the American College of Rheumatology (ACR) 20 measurement of response. These results were statistically significant when compared with placebo (p=0.0024). The antibody combination with methotrexate was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.

"We are greatly encouraged by this demonstration of efficacy from a well-designed and well-executed study," said Howard H. Pien, Chairman and CEO of Medarex. "These results show that by targeting the chemokine IP-10 with our MDX-1100 antibody, we may be able to offer a potentially important and novel treatment option for rheumatoid arthritis and potentially other inflammatory indications."

"Based on these positive results with a novel pro-inflammatory target, we are actively preparing for the next stage of clinical development for MDX-1100 in RA, including the potential for subcutaneous dosing," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We also look forward to exploring the broader potential of MDX-1100 in a range of i
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 After 6 months of careful ... here - the new programme for the next Cool Chain ... our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and ... that is broad and yet specific, focused and yet accessible, ...
(Date:9/18/2014)... Calif. , Sept. 18, 2014   ... ), a biopharmaceutical company leading the discovery and ... it has initiated its ATHENA natural history of ... life-threatening genetic kidney disease with no approved therapy. ... natural decline of renal function markers such as ...
(Date:9/18/2014)... , Sept. 18, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that the ... Geert Cauwenbergh , will present at ... Conference on Wednesday, September 24, 2014 at ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... MADISON, N.J., March 28, 2011 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today it ... subsidiary, Spark Acquisition Corporation, for all of the outstanding ... (Nasdaq: CRA ), one of the world,s ...
... (Nasdaq: VRUS ) today announced that it will ... Study of the Liver (EASL) on Saturday, April 2, 2011 ... Pharmasset,s progress on the programs that are the subject of ... a simultaneous webcast of this event via the internet, log ...
Cached Medicine Technology:Quest Diagnostics Commences Tender Offer for Acquisition of Celera 2Quest Diagnostics Commences Tender Offer for Acquisition of Celera 3Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 Clinical ... provides data on the Edema clinical trial scenario. This ... clinical trials on Edema. It includes an overview of ... the site of trial conduction across the globe. The ... by their phase, trial status, prominence of the sponsors ...
(Date:9/18/2014)... Springs, LA (PRWEB) September 18, 2014 This past ... got a kiss from Roy at the kissing booth during the ... “Bo” Bryant Animal Shelter. “I have loved animals my whole ... with most of those animals being strays who needed a home. ... animals since I can’t take them all home!” , The CEO ...
(Date:9/18/2014)... Cary, NC (PRWEB) September 18, 2014 Relias ... the health and human services markets, today announced it has ... the fastest growing private companies in America. , In the ... growth, and moved up almost 2,000 spots on the Inc. ... in 2012. , “The industries we serve continue ...
(Date:9/18/2014)... Schaumburg, IL (PRWEB) September 18, 2014 ... proving itself a boon to contractors and homeowners ... construction dust that overtakes the home, causes potential ... project. Now available nationwide, the BuildClean system allows ... from demolition, sanding and other standard remodeling tasks. ...
(Date:9/18/2014)... Maureen Salamon HealthDay ... -- Migraines in midlife may be associated with increased ... in later years, new research suggests. The study, ... two brain-based conditions, also suggested that the migraine-Parkinson,s association ... An aura is a warning sign of a pending ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3
... KENILWORTH, N.J., July 24 Schering-Plough Corporation (NYSE: ... Court approval, to resolve litigation seeking to enjoin the planned ... relief. The consolidated class action lawsuits, previously reported in ... in U.S. District Court for the District of New Jersey. ...
... , , , ... ( www.medworksusa.org ) will provide free access for the uninsured ... a.m. to 4 p.m. Saturday and Sunday, July 25 and 26, at ... mass health clinic sponsored by MedWorks and will provide 1100 medical, 300 ...
... WASHINGTON, July 24 Medicine and healing have long been ... years, the debate about the nature of the relationship between ... book, "Spirituality and Medicine: Can the Two Walk Together?" ( ... Ph.D., J.D., M.Div., and Harold B. Betton, M.D., Ph.D., offer ...
... LINTHICUM, Md., July 24 Dialysis Corporation of America (Nasdaq: ... second quarter 2009 financial results on Wednesday August 5, 2009, after ... conference call in conjunction with its second quarter 2009 earnings release ... , , Those interested in ...
... Foundation Radiology Group (FRG), the premier provider of diagnostic imaging ... the addition of Jim Yamshak, Senior Vice President of Sales, ... , , Jim Yamshak, a ... to the FRG team. Most recently, Mr. Yamshak served as ...
... ARBOR, Mich., July 24 As the economy continues to falter, a ... to spend what money they have, and children -- especially those who ... more at risk because of it. , , ... in May 2009 shows 44 percent of families, financial situations have worsened ...
Cached Medicine News:Health News:Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:'Spirituality and Medicine: Can the Two Walk Together?' 2Health News:Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 2Health News:Foundation Radiology Group Builds Sales and Marketing Teams for Projected Record-Year Growth 2Health News:Foundation Radiology Group Builds Sales and Marketing Teams for Projected Record-Year Growth 3Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 2Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 3
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: